FDA extends Eli Lilly's orforglipron review to April 10, wiping $35B from market cap as Novo Nordisk's oral Wegovy gains three-month head start.

Lilly Stock Drops 4% as FDA Delays Obesity Pill, Handing Novo Crucial Head Start

FDA removes suicide warnings from Wegovy, Zepbound, Saxenda after finding no link. $63B GLP-1 market gets regulatory boost for Lilly and Novo.

FDA Removes Suicide Warnings From Blockbuster Weight-Loss Drugs Wegovy and Zepbound

Eli Lilly preparing €15B Abivax bid for IBD drug obefazimod. Stock surges 30% to record high. What it means for pharma's M&A wave.